| - |
Lacosamide |
Vimpat® |
As monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age). |
Rapid Review Complete |
31st October 2017 |
 |
| __ |
Lanadelumab |
Takhzyro® |
For routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. |
Assessment process complete |
26th June 2020 |
|
| - |
Lapatinib |
Tyverb® |
For the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer. |
Assessment process complete |
28th January 2008 |
|
| 19050 |
Larotrectinib |
Vitrakvi® |
For patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 21053 |
Latanoprost/Timolol |
Fixapost® |
In adults (including the elderly) for the reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta‐blockers or prostaglandin analogues. |
Rapid Review Complete |
6th December 2021 |
|
| - |
Ledipasvir/sofosbuvir |
Harvoni® |
For the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4) in adults. |
Assessment process complete |
20th November 2015 |
|
| - |
Lenalidomide |
Revlimid® |
For the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension). |
Rapid Review Complete |
20th November 2015 |
|
| - |
Lenvatinib |
Kisplyx® |
In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy. |
Rapid Review Complete |
18th May 2017 |
|
| 22057 |
Lenvatinib |
Kisplyx® |
For the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment |
Rapid Review Complete |
22nd September 2022 |
|
| - |
Lenvatinib |
Lenvima® |
For the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine. |
Rapid Review Complete |
10th July 2015 |
|
| - |
Lenvatinib |
Lenvima® |
As monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy. |
Rapid Review Complete |
16th August 2018 |
|
| - |
Lesinurad |
Zurampic® |
For the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor. |
Assessment process complete |
6th December 2018 |
|
| - |
Letermovir |
Prevymis® |
For the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT). |
Assessment process complete |
20th May 2020 |
|
| - |
Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel |
Duodopa® |
For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted. |
Assessment process complete |
14th June 2019 |
|
| 21068 |
Levodopa/carbidopa/entacapone intestinal gel |
Lecigon® |
For the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson’s medicinal products have not given satisfactory results. |
Rapid Review Complete |
17th February 2022 |
|
| - |
Levofloxacin |
Quinsair® |
For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis. |
Rapid Review Complete |
2nd March 2016 |
|
| - |
Levonorgestrel intrauterine delivery system LNG IUS 12 |
Kyleena® |
For contraception for up to 5 years. |
Rapid Review Complete |
16th March 2017 |
|
| - |
Levonorgestrel Intrauterine System |
Levosert® |
For contraception and for the treatment of heavy menstrual bleeding. |
Rapid Review Complete |
23rd October 2019 |
|
| - |
Levonorgestrel intrauterine system LNG-IUS |
Jaydess® |
For contraception for up to three years. |
Rapid Review Complete |
26th March 2013 |
|
| - |
Lidocaine 5% plasters |
Versatis® |
For the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN). |
Assessment process complete |
24th September 2015 |
|
| - |
Linaclotide |
Constella® |
For the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults. |
Rapid Review Complete |
28th June 2013 |
|
| - |
Linagliptin |
Trajenta® |
For treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. |
Rapid Review Complete |
6th September 2011 |
|
| 23068 |
Linzagolix |
Yselty® |
Linzagolix is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
Awaiting full HTA submission from Applicant |
16th April 2024 |
|
| - |
Lipegfilgrastim |
Lonquex® |
For reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). |
Rapid Review Complete |
24th September 2013 |
|
| 23080 |
Lipegfilgrastim |
Lonquex® |
Lipegfilgrastim is indicated in adults and in children two years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Lipegfilgrastim is currently reimbursed on High Tech Drug Arrangement for use in adults and reimbursement is sought for children two years of age and older. |
Rapid Review Complete |
27th February 2024 |
|
| - |
Liposomal daunorubicin and cytarabine |
Vyxeos Liposomal® |
For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes. |
Assessment process complete |
16th April 2020 |
|
| - |
Liquid Paraffin Ointment |
VitA-POS Opthalmic® |
For the treatment of mild to moderate form of dry eye. |
Rapid Review Complete |
31st January 2014 |
|
| 24001 |
Liraglutide |
Saxenda® |
Liraglutide is indicated as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: • obesity (body mass index (BMI) corresponding to ≥30 kg/m2 for adults by international cut-off points) and • body weight above 60 kg* |
Rapid Review Complete |
9th February 2024 |
|
| 19039 |
Liraglutide |
Saxenda® |
As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is, as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease. |
Assessment process complete |
10th February 2021 |
|
| - |
Liraglutide |
Victoza® |
For treatment of adults with type 2 diabetes mellitus. |
Assessment process complete |
7th March 2019 |
|
| - |
Lisdexamfetamine dimesylate |
Tyvense® |
For Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. |
Rapid Review Complete |
28th February 2013 |
|
| __ |
__ |
__ |
__ |
__ |
7th August 2014 |
|
| - |
Lomitapide |
Lojuxta® |
As an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). |
Rapid Review Complete |
15th September 2014 |
|
| 23053 |
Loncastuximab tesirine |
Zynlonta® |
Loncastuximab tesirine (Zynlonta®) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. |
Rapid Review Complete |
1st September 2023 |
|
| - |
Lorlatinib |
Lorviqua® |
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on: (i) alectinib or ceritinib as the first ALK-targeted treatment, or (ii) crizotinib and at least one other ALK-targeted treatment. |
Rapid Review Complete |
25th June 2019 |
|
| 21071 |
Lorlatinib |
Lorviqua® |
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. |
Rapid Review Complete |
13th January 2022 |
|
| - |
Lornoxicam |
Xefo® |
For the short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis |
Rapid Review Complete |
7th July 2011 |
|
| - |
Loteprednol |
Lotemax 0.5% eye drops suspension |
For treatment of post-operative inflammation following ocular surgery. |
Rapid Review Complete |
5th December 2011 |
|
| - |
Loxapine inhalation powder |
Adasuve® |
For the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. |
Rapid Review Complete |
28th July 2016 |
|
| - |
Lumacaftor/ivacaftor |
Orkambi® |
For the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. |
Assessment process complete |
14th March 2024 |
|
| - |
Lutetium (177Lu) Oxodotreotide |
Lutathera® |
For the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. |
Assessment process complete |
11th February 2020 |
|
| 23002 |
Lutetium (177Lu) vipivotide tetraxetan |
Pluvicto® |
Lutetium (177Lu) vipivotide tetraxetan in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. |
NCPE assessment ongoing |
5th February 2024 |
|
